320 results on '"Shah, Jay B."'
Search Results
2. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer
3. MP71-19 ULTRASENSITIVE URINARY LIQUID BIOPSY ANALYSIS FOR BCG RESPONSE ASSESSMENT IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
4. PD30-03 PREDICTING RESPONSE TO INTRAVESICAL BCG IN HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER USING AN ARTIFICIAL INTELLIGENCE-POWERED PATHOLOGY ASSAY: DEVELOPMENT AND VALIDATION IN AN INTERNATIONAL 12 CENTER COHORT
5. PD27-12 DEVELOPMENT AND VALIDATION OF GENERALIZABLE INTERPRETABLE AI BIOMARKERS TO PREDICT CLINICAL OUTCOMES IN BCG-TREATED PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER
6. Risk of hospitalisation after primary treatment for prostate cancer
7. Perioperative Blood Transfusion Is Associated with Worse Survival in Patients Undergoing Radical Cystectomy after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
8. The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy
9. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort
10. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy
11. Neurocognitive deficits in older patients with cancer
12. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy
13. Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study
14. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer
15. Patient Positioning and Safety in Steep Trendelenburg
16. Critical Appraisal of Quality Improvement Publications in the Urological Literature
17. The Impact of Early Exposure to Urology: Evaluation of an Introductory Preclinical Course
18. Reply by Authors
19. Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience
20. A Leak in the System: Addressing the Environmental Impact of Urologic Care
21. Clinical Outcomes of cT1 Micropapillary Bladder Cancer
22. Dose dense MVAC prior to radical cystectomy: a real-world experience
23. Problema: contraccezione maschile
24. Problema: disfunzione sessuale
25. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer
26. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy
27. Strategies for Optimizing Bacillus Calmette-Guérin
28. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?
29. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy
30. MP72-02 OUTCOME OF PATIENTS WITH MICROPAPILLARY BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY WITH/WITHOUT NEOADJUVANT CHEMOTHERAPY
31. MP67-06 POST-OPERATIVE WOUND INFECTIONS AND STEROID USE ARE INDEPENDENT RISK FACTORS FOR MIDLINE FASCIAL DEFECTS IN PATIENTS AFTER RADICAL CYSTECTOMY WITH ILEAL CONDUIT
32. PD41-05 FINAL PATHOLOGIC STAGE AFTER NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR BLADDER CANCER: DOES PT0 PREDICT BETTER SURVIVAL THAN PTA/PTIS/PT1?
33. MP65-06 A MULTI-INSTITUTIONAL ANALYSIS OF OUTCOMES IN PATIENTS WITH CLINICALLY NODE POSITIVE UROTHELIAL BLADDER CANCER TREATED WITH INDUCTION CHEMOTHERAPY AND RADICAL CYSTECTOMY
34. PD31-09 CLINICAL FACTORS PREDICTING PATHOLOGICAL POSITIVE LYMPH NODES IN CLINICALLY NODE NEGATIVE PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY
35. MP26-14 MEASURING SUCCESS AFTER RADICAL CYSTECTOMY: FEASIBILITY OF A NOVEL COMPOSITE ENDPOINT (“POOR RECOVERY”) TO QUANTIFY OUTCOMES AFTER SURGERY
36. Friend or foe? Role of peroxisome proliferator-activated receptor-γ in human bladder cancer
37. Bupivacaine local anesthetic to decrease opioid requirements after radical cystectomy: Does formulation matter?
38. Prostate Biopsy Patterns in the CaPSURE Database: Evolution With Time and Impact on Outcome After Prostatectomy
39. Physician Variation in Management of Low-Risk Prostate Cancer: A Population-Based Cohort Study
40. PATHOLOGIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN A MULTICENTRE COHORT OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER.: MP55-08
41. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers
42. Deglutition Syncope After Variceal Band Ligation
43. Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer
44. New treatments for superficial bladder cancer
45. Changes in Prognostic Significance and Predictive Accuracy of Gleason Grading System Throughout PSA Era: Impact of Grade Migration in Prostate Cancer
46. Demographic analysis of randomized controlled trials in bladder cancer
47. Does year of radical prostatectomy independently predict outcome in prostate cancer?
48. Robot-assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient selection needs
49. Fluorescence Cystoscopy for Nonmuscle Invasive Bladder Cancer
50. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.